Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)

NCT05254782 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05254782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05254782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Recruiting
Start date
July 6, 2021
Completion date
March 31, 2028
Enrollment
360 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer